Throat cancer is relatively uncommon. It does not rank among the top 10 cancers in the United States, and cancers of the oral cavity and pharynx combined account for about 2.9% of all new cancer diagnoses, with an estimated 60,480 new cases expected in 2026. Laryngeal cancer (cancer of the voice box) is even rarer, making up just 0.6% of all new cancers, with roughly 12,290 new cases per year.
That said, “uncommon” does not mean unimportant. Certain groups face significantly higher risk, and the number of cases linked to HPV has been rising. Here’s what the numbers actually look like and who needs to pay attention.
How Throat Cancer Compares to Other Cancers
To put throat cancer in context, consider the cancers diagnosed most often in the U.S. Prostate cancer leads with roughly 334,000 new cases per year, followed by female breast cancer at about 322,000 and lung cancer at 229,000. Colorectal cancer, melanoma, and bladder cancer each produce between 85,000 and 159,000 new cases annually. Oral cavity and pharynx cancers, at around 60,000 cases, fall just outside the top 10. Laryngeal cancer, at about 12,000 cases, is far less frequent still.
So while tens of thousands of people receive a throat cancer diagnosis each year, your individual lifetime odds are low compared to more prevalent cancers like breast, prostate, lung, or colon cancer.
What “Throat Cancer” Actually Includes
Throat cancer is not a single disease. It’s an umbrella term that covers several distinct cancers grouped by location:
- Laryngeal cancer: Forms in the voice box (larynx), including the vocal cords. About 12,290 new cases are diagnosed per year in the U.S.
- Pharyngeal cancer: Forms in the pharynx, the tube running from behind the nose down to the esophagus. This is further divided into the nasopharynx (upper), oropharynx (middle, behind the mouth), and hypopharynx (lower).
Oropharyngeal cancer has drawn particular attention in recent years because of its connection to HPV. The CDC estimates that about 70% of oropharyngeal cancers are caused by HPV, making this subtype the one most clearly on the rise even as smoking-related throat cancers have declined.
Who Is Most at Risk
Throat cancer affects men far more often than women, and most diagnoses occur in people over 50. But the single biggest factor shaping your risk is tobacco and alcohol use, especially in combination.
A large pooled analysis published in Cancer Epidemiology, Biomarkers & Prevention found that smoking alone roughly doubles the risk of head and neck cancer among people who don’t drink. Alcohol use alone, without tobacco, barely moves the needle. But using both together creates a risk that is more than multiplicative. People who smoke more than 20 cigarettes a day and drink three or more alcoholic beverages daily face about 14 times the risk of someone who neither smokes nor drinks. The combined effect is far greater than you would get by simply adding the two risks together.
HPV is the other major risk factor, particularly for oropharyngeal cancer. HPV-related throat cancers tend to appear in younger adults who may have no history of heavy smoking or drinking, which is part of why this subtype has been increasing even as tobacco-driven cases fall.
Where Throat Cancer Is More Common Globally
Throat cancer rates vary dramatically by region. South America, Europe, western Asia, and Russia consistently show the highest incidence, largely driven by higher rates of smoking and alcohol consumption. In women, pockets of higher incidence appear in South America, India, and the United States.
Occupational exposure to dust, chemicals, and fumes plays a larger role in low-income countries, where workplace safety standards tend to be weaker. Indoor air pollution has also been implicated in head and neck tumors in parts of Europe. In China, rising rates have been linked to increased environmental pollution and a dietary shift toward higher-fat, Western-style eating patterns.
Survival Rates by Location and Stage
Survival depends heavily on where in the throat the cancer forms and how far it has spread at diagnosis. Five-year survival rates from the American Cancer Society, based on cases diagnosed between 2015 and 2021, illustrate the range:
Cancer on the vocal cords (glottis) has the best outlook. When caught before it spreads, the five-year survival rate is 85%. That drops to 56% if it reaches nearby lymph nodes and 48% if it has spread to distant sites. The vocal cords have an advantage: even a small tumor there causes noticeable hoarseness, which often leads to earlier detection.
Cancer above the vocal cords (supraglottis) and below them (subglottis) both carry a five-year survival rate around 60% when localized, dropping to roughly 48-50% with regional spread and 30-45% at the distant stage.
Hypopharyngeal cancer has the poorest prognosis. Even when localized, the five-year survival rate is 61%, and it falls sharply to 36% with regional spread and just 20% when distant. This area produces subtler symptoms, so these cancers are more often caught late.
Symptoms Worth Knowing
Because throat cancer is uncommon, most sore throats and bouts of hoarseness are caused by infections, allergies, or vocal strain. The distinction lies in persistence. Clinical guidelines flag hoarseness that lasts more than three to four weeks without improving, or a sore throat that persists beyond two to three weeks, as symptoms that warrant investigation.
Other signs include difficulty swallowing, unexplained ear pain on one side, a lump in the neck, or unintended weight loss. None of these symptoms are specific to cancer, but when they linger without an obvious cause, they merit a closer look. Early-stage throat cancers, particularly those on the vocal cords, are highly treatable when caught before they spread.
The HPV Factor
The rising share of HPV-driven oropharyngeal cancers has shifted who gets throat cancer and how it behaves. HPV-positive oropharyngeal cancers tend to respond better to treatment than HPV-negative cancers, and patients with these tumors generally have better outcomes. About 70% of oropharyngeal cancers are now attributable to HPV, according to CDC estimates.
HPV vaccination, which is recommended for preteens and available through age 26 (and in some cases up to 45), targets the viral strains responsible for these cancers. Over time, widespread vaccination is expected to reduce the incidence of HPV-related throat cancers, though the full impact will take decades to materialize since these cancers typically develop years after initial infection.